To rule out potential off-target effects of ritanserin, related to its known activity as serotonin 5-HT2A and 5-HT2C receptors antagonist, AML cells were treated with three additional serotonin receptors inhibitors: risperidone, metoclopramide, and altanserin. This evidence concerns the gene HTR2A and acute myeloid leukemia.